# A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

> **NCT00752518** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 35 (actual)

## Conditions studied

- Refractory
- Multiple Myeloma
- Relapse

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00752518
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2006-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752518, "A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00752518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*